Drug Trial Radar · NCT04396821
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
May 28, 2020
Primary completion
Jun 30, 2027
Study completion Sep 30, 2027
Sponsor
- Lead sponsor
- Transcenta Therapeutics (Hangzhou) Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Bristol-Myers Squibb
- First posted
- May 21, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label Phase I/IIa, First in Human trial of TST001, a recombinant humanized anti-Claudin 18.2 (CLDN18.2) IgG1 monoclonal antibody as monotherapy or in combination with nivolumab or standard of care. It is being tested against advanced and/or metastatic solid tumors including gastric, gastroesophageal junction, pancreatic cancers.
Conditions
- Advanced Cancer
- Gastric Cancer
- Gastroesophageal-junction Cancer
- Pancreatic Cancer
Interventions
TST001Drug
TST001 is a humanized IgG1 monoclonal antibody.
Nivolumab Injection [Opdivo]Drug
Nivolumab is one of the PD-1 checkpoint inhibitors, and has proved clinical benefit for multiple late-stage malignancies
mFOLFOX6Drug
mFOLFOX6 is a combination chemotherapy regimen including the drugs leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin.
GemcitabineDrug
Chemotherapy medication
Albumin-Bound PaclitaxelDrug
Chemotherapy medication
Primary outcomes
What the sponsor says the trial is designed to measure.
- Participant Safety as characterized by frequency and severity of adverse eventsTime frame: up to 100 days following last dose
- Maximum Tolerated Dose (MTD or Recommended Phase 2 Dose (RP2D)Time frame: up to 100 days following last dose
- Participant Safety and Tolerability of TST001 in combination with Nivolumab as characterized by frequency and severity of adverse eventsTime frame: Up to 100 days following last dose
- Participant Safety and Tolerability of TST001 in combination with Nivolumab and mFOLFOX6 as characterized by frequency and severity of adverse eventsTime frame: Up to 100 days following last dose
- Participant Safety and Tolerability of TST001 in combination with gemcitabine and albumin-bound paclitaxel as characterized by frequency and severity of adverse eventsTime frame: Up to 100 days following last dose
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
Banner MD Anderson
Gilbert, Arizona
University of Arizona
Tucson, Arizona
Yale University
New Haven, Connecticut
Florida Cancer Specialists
Sarasota, Florida
Emory University
Atlanta, Georgia
University of Kansas, School of Medicine
Kansas City, Kansas
Washington University
St Louis, Missouri
Memorial Sloan Kettering
New York, New York
Stony Brook Cancer Center
Stony Brook, New York
Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina
Gabrail Cancer Research
Canton, Ohio
Pennsylvania Cancer Specialist Research Institute
Gettysburg, Pennsylvania
Allegheny Hospital
Pittsburgh, Pennsylvania
Sarah Cannon Research Institute
Nashville, Tennessee
Vanderbilt University
Nashville, Tennessee
NEXT Oncology
Austin, Texas
Swedish Cancer Institute
Seattle, Washington
Medical College of Wisconsin
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.